**Peter Mac publications 2021**

**January**


February


28. Leleu X, Beksac M, Chou T, Dimopoulos M, Yoon SS, Prince HM, Pour L, Obreja M, Qi M, Siegel D. Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. Leukemia & Lymphoma 2021;62:358-367.


March


46. Lewis AC, Kats LM. Non-genetic heterogeneity, altered cell fate and differentiation therapy. EMBO Molecular Medicine 2021;13:e12670.


April


May


microsatellite instability assay with routine molecular methods and immunohistochemistry on formalin-fixed paraffinembedded tissue of colorectal cancer. Virchows Archiv 2021;478:851-863.


June


CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. Cell 2021;184:3143-62.


July


38


August


44. Longhitano AP, Slavin MA, Harrison SJ, Teh BW. Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap. Blood Reviews 2021;49:100810.


55. Pojer JM, Manning SA, Kroeger B, Kondo S, Harvey KF. The Hippo pathway uses different machinery to control cell fate and organ size. iScience 2021;24:102830.


September


October


87. Seymour JF. The tools to choose: applying indirect treatment comparisons to the selection of frontline targeted therapy for CLL. Leukemia & Lymphoma 2021;62:2299-2302.


function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood 2021;137:2721-35.


November


December


7. Cochrane T, Campbell BA, Gangatharan SA, Latimer M, Khor R, Christie DRH, Gilbertson M, Ratnasingam S, Palfreyman E, Lee HP, Trotman J, Hertzberg M, Dickinson M. Assessment and


45. Richards SJG, Udayasiri DK, Jones IT, Hastie IA, Chandra R, McCormick JJ, Chittleborough TJ, Read DJ, Hayes IP. Delayed ileostomy closure increases the odds of Clostridium difficile infection. Colorectal Disease 2021;23:3213-3219.


